Literature DB >> 32500342

Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group.

Alexandre Doussot1, Dewi Vernerey2, Eric Rullier3, Jérémie H Lefevre4, Hélène Meillat5, Eddy Cotte6, Guillaume Piessen7, Jean-Jacques Tuech8, Yves Panis9, Diane Mege10, Aurélia Meurisse2, Berardino De Bari11,12, Bruno Heyd1, Zaher Lakkis13.   

Abstract

BACKGROUND: Synchronous prostate cancer (PC) and rectal cancer (RC) is a rare clinical situation. While combining curative-intent management for both cancers can be challenging, available data for guiding the multidisciplinary strategy are lacking.
METHODS: Consecutive patients undergoing rectal resection for a mid-low RC with synchronous PC treated at 9 tertiary-care centers between 2008 and 2018 were included. Management strategy and data on postoperative and long-term outcomes were retrospectively analyzed.
RESULTS: Overall, 25 patients underwent curative-intent RC resection combined with PC management. Nine (36%), 10 (40%) and 6 (24%) patients had low-, intermediate-, and high-risk PC, respectively. Management mostly consisted of chemoradiotherapy combined in 18 patients (72%) with either TME in 12 patients or pelvic exenteration for resection of both cancers in 6 patients. Most patients underwent RC resection using a laparoscopic approach (n = 16, 64%). Anastomosis was performed in 18 patients (72%) of whom 13 received diverting ileostomy. The complete R0 resection rate was 96% (n = 24). The overall morbidity rate was 64% (n = 16) and 5 patients (20%) experienced severe surgical morbidity of which two died within 90 days of surgery after pelvic exenteration. Among patients with anastomosis, 2 patients (11%) experienced anastomotic leak requiring surgical management. After a median follow-up of 31.2 months, 3-year OS and RFS were 80.2% (CI 95% 58.8-92.2) and 68.6% (CI 95% 42.3-84.8), respectively.
CONCLUSIONS: This series is the largest to report that simultaneous curative-intent management of synchronous PC and RC is feasible and safe. Pelvic exenteration might be a better option when RC complete resection seems not achievable through TME.

Entities:  

Mesh:

Year:  2020        PMID: 32500342     DOI: 10.1245/s10434-020-08683-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

1.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

2.  ASO Author Reflections: Major Morbidity After Extended Radical Resections for Locally Advanced and Recurrent Pelvic Malignancies.

Authors:  Oliver Peacock; Peadar S Waters; Frank A Frizelle; Jacob J McCormick
Journal:  Ann Surg Oncol       Date:  2019-11-04       Impact factor: 5.344

3.  Pushing the boundaries of pelvic exenteration by maintaining survival at the cost of morbidity.

Authors:  R L Venchiarutti; M J Solomon; C E Koh; J M Young; D Steffens
Journal:  Br J Surg       Date:  2019-07-08       Impact factor: 6.939

4.  Morbidity and oncological outcomes of rectal cancer impaired by previous prostate malignancy.

Authors:  Z Lakkis; D Vernerey; D Mege; J-L Faucheron; Y Panis; J-J Tuech; J H Lefevre; A Brouquet; F Dumont; C Borg; A-S Woronoff; A Meurisse; B Heyd; E Rullier
Journal:  Br J Surg       Date:  2019-05-10       Impact factor: 6.939

5.  Management of rectal cancer: the 2016 French guidelines.

Authors:  Z Lakkis; G Manceau; V Bridoux; A Brouquet; S Kirzin; L Maggiori; C de Chaisemartin; J H Lefevre; Y Panis
Journal:  Colorectal Dis       Date:  2017-02       Impact factor: 3.788

6.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

7.  The curative management of synchronous rectal and prostate cancer.

Authors:  Naomi A Lavan; Dara O Kavanagh; Joseph Martin; Cormac Small; Myles R Joyce; Clare M Faul; Paul J Kelly; Michael O'Riordain; Charles M Gillham; John G Armstrong; Osama Salib; Deborah A McNamara; Gerard McVey; Brian D P O'Neill
Journal:  Br J Radiol       Date:  2015-11-05       Impact factor: 3.039

8.  Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy.

Authors:  Victoria A Harris; John Staffurth; Olivia Naismith; Alikhan Esmail; Sarah Gulliford; Vincent Khoo; Rebecca Lewis; John Littler; Helen McNair; Azmat Sadoyze; Christopher Scrase; Aslam Sohaib; Isabel Syndikus; Anjali Zarkar; Emma Hall; David Dearnaley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-30       Impact factor: 7.038

9.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

Review 10.  Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum.

Authors:  G F Nash; K J Turner; T Hickish; J Smith; M Chand; B J Moran
Journal:  Ann R Coll Surg Engl       Date:  2012-10       Impact factor: 1.891

View more
  1 in total

Review 1.  Prostate Cancer Diagnosis, Treatment and Outcomes in Patients with Previous or Synchronous Colorectal Cancer: A Systematic Review of Published Evidence.

Authors:  Giuseppe Celentano; Massimiliano Creta; Luigi Napolitano; Marco Abate; Roberto La Rocca; Marco Capece; Claudia Mirone; Simone Morra; Francesco Di Bello; Luigi Cirillo; Francesco Mangiapia; Gianluigi Califano; Claudia Collà Ruvolo; Caterina Sagnelli; Antonello Sica; Armando Calogero; Fabrizio Iacono; Ferdinando Fusco; Vincenzo Mirone; Nicola Longo
Journal:  Diagnostics (Basel)       Date:  2022-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.